What is Avanos Medical, Inc.'s earnings per share (EPS)?

Avanos Medical, Inc. (AVNS) reported diluted earnings per share of -$1.57 for fiscal year 2025. This represents a 81.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Avanos Medical, Inc. (AVNS) Financials

AVNS

Trailing 12 months to March 31, 2026

Revenue $715.9M +3.9% YoY

Net Income -$74.4M +80.7% YoY

EPS (Diluted) -$1.60 +80.9% YoY

Free Cash Flow $7.5M -93.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVNS SEC filings page.

Avanos Medical, Inc. (AVNS) reported $715.9M in revenue over the twelve months to Mar 31, 2026, up 3.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVNS FY2025 2026-08-29

Avanos converts operating cash despite sharp accounting losses, while gross-margin compression and asset contraction reshape the business's financial profile.

The key split is between earnings and cash generation: net losses reached $392.1M in FY2024 and $72.9M in FY2025, yet operating cash flow stayed positive at $100.7M and $74.7M. That divergence indicates reported losses were not a direct proxy for current-period cash generation, although free cash flow fell to $43.1M in FY2025 as capital spending increased.

Gross economics weakened even as sales held up: revenue increased to $701.2M in FY2025, while gross margin compressed to 50.5%. Operating margin improved sharply from -57.6% in FY2024 to -8.8%, showing that FY2024's unusually severe operating loss was not repeated at the same scale, but profitability remained negative.

The balance sheet is becoming smaller and less debt-heavy: total liabilities declined to $295.5M and debt-to-equity was just 0.1x in FY2025. However, equity fell from $1.24B in FY2023 to $778.2M in FY2025, so deleveraging has occurred alongside substantial erosion of accumulated capital.

Financial Health Signals

Financial Health Score 44/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Avanos Medical, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Avanos Medical, Inc. has an operating margin of -8.8%, meaning the company loses $9 on every $100 of revenue. This results in a profitability score of 13/100. This is up from -57.6% the prior year.

Growth

Avanos Medical, Inc.'s revenue grew a modest 1.9% year-over-year to $701.2M. This slow but positive growth earns a score of 38/100.

Leverage

Avanos Medical, Inc. carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Avanos Medical, Inc.'s current ratio of 2.15 indicates adequate short-term liquidity, earning a score of 63/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Avanos Medical, Inc. has a free cash flow margin of 6.2%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Avanos Medical, Inc. posts a -9.4% return on equity (ROE), meaning it loses $9 for every $100 of shareholders' equity. This results in a returns score of 15/100. This is up from -47.3% the prior year.

Altman Z-Score Grey Zone

2.04

Avanos Medical, Inc. scores 2.04, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($295.5M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Avanos Medical, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

Avanos Medical, Inc. reported a net loss of $72.9M while generating $74.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Avanos Medical, Inc. reported an operating loss of $61.6M against $7.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$182.2M

YoY+8.8%

QoQ+0.7%

5Y CAGR+0.2%

Avanos Medical, Inc. generated $182.2M in revenue in Q1 2026. This represents an increase of 8.8% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

EBITDA

$19.1M

YoY-4.0%

QoQ+165.3%

Avanos Medical, Inc.'s EBITDA was $19.1M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.0% from the same quarter a year earlier. Against the prior quarter it is up 165.3%.

Net Income

$5.1M

YoY-22.7%

QoQ+492.3%

Avanos Medical, Inc. reported $5.1M in net income in Q1 2026. This represents a decrease of 22.7% from the same quarter a year earlier. Against the prior quarter it is up 492.3%.

EPS (Diluted)

$0.11

YoY-21.4%

QoQ+650.0%

10Y CAGR-9.5%

Avanos Medical, Inc. earned $0.11 per diluted share (EPS) in Q1 2026. This represents a decrease of 21.4% from the same quarter a year earlier. Against the prior quarter it is up 650.0%.

Cash & Balance Sheet

Free Cash Flow

-$16.6M

YoY-187.4%

QoQ-177.9%

Avanos Medical, Inc. recorded an outflow of $16.6M in free cash flow in Q1 2026, representing a cash shortfall after capex. This represents a decrease of 187.4% from the same quarter a year earlier. Against the prior quarter it is down 177.9%.

Cash & Debt

$65.6M

YoY-32.4%

QoQ-26.9%

5Y CAGR-8.1%

10Y CAGR-8.8%

Avanos Medical, Inc. held $65.6M in cash against $87.3M in long-term debt as of Q1 2026.

Shares Outstanding

47M

YoY+1.3%

QoQ+0.7%

5Y CAGR-0.5%

10Y CAGR0.0%

Avanos Medical, Inc. had 47M shares outstanding in Q1 2026. This represents an increase of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

51.7%

YoY-1.9pp

QoQ+4.2pp

5Y change+1.2pp

Avanos Medical, Inc.'s gross margin was 51.7% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.

Operating Margin

4.9%

YoY-1.3pp

QoQ+3.5pp

5Y change+11.7pp

Avanos Medical, Inc.'s operating margin was 4.9% in Q1 2026, reflecting core business profitability. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.

Net Margin

2.8%

YoY-1.1pp

QoQ+3.5pp

5Y change+7.4pp

Avanos Medical, Inc.'s net profit margin was 2.8% in Q1 2026, showing the share of revenue converted to profit. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.

Return on Equity

0.7%

YoY-0.1pp

QoQ+0.8pp

5Y change+1.3pp

Avanos Medical, Inc.'s ROE was 0.7% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.

Capital Allocation

R&D Spending

$5.2M

YoY-3.7%

QoQ-14.8%

5Y CAGR-8.9%

Avanos Medical, Inc. invested $5.2M in research and development in Q1 2026. This represents a decrease of 3.7% from the same quarter a year earlier. Against the prior quarter it is down 14.8%.

Share Buybacks

$1.3M

YoY-40.9%

QoQ+333.3%

Avanos Medical, Inc. spent $1.3M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 40.9% from the same quarter a year earlier. Against the prior quarter it is up 333.3%.

Capital Expenditures

$4.3M

YoY-35.8%

QoQ-37.7%

5Y CAGR-5.5%

10Y CAGR-6.0%

Avanos Medical, Inc. invested $4.3M in capex in Q1 2026, funding long-term assets and infrastructure. This represents a decrease of 35.8% from the same quarter a year earlier. Against the prior quarter it is down 37.7%.

AVNS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVNS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$715.9M	$701.2M+1.9%	$687.8M+2.2%	$673.3M-1.6%	$684.1M+16.5%	$587.0M-17.9%	$714.8M+2.5%	$697.6M+6.9%	$652.3M+6.7%	$611.6M+8.0%	$566.2M+11.2%	$509.0M-69.6%	$1.7B-0.3%	$1.7B-0.4%	$1.7B
Cost of Revenue	$357.6M	$347.3M+13.3%	$306.5M+4.4%	$293.6M+1.3%	$289.9M+0.7%	$287.8M-16.3%	$343.9M+16.4%	$295.4M+13.0%	$261.4M-4.8%	$274.7M+2.1%	$269.0M+7.1%	$251.2M-77.6%	$1.1B+5.5%	$1.1B-1.5%	$1.1B
Gross Profit	$358.3M	$353.9M-7.2%	$381.3M+0.4%	$379.7M-3.7%	$394.2M+31.8%	$299.2M-19.3%	$370.9M-7.8%	$402.2M+2.9%	$390.9M+16.0%	$336.9M+13.4%	$297.2M+15.3%	$257.8M-53.0%	$548.6M-10.4%	$612.2M+1.6%	$602.5M
R&D Expenses	$23.1M	$23.3M-11.1%	$26.2M-3.7%	$27.2M-6.8%	$29.2M-4.6%	$30.6M-12.3%	$34.9M-7.4%	$37.7M-9.8%	$41.8M+9.4%	$38.2M-0.5%	$38.4M+39.1%	$27.6M-17.9%	$33.6M-11.3%	$37.9M+14.8%	$33.0M
SG&A Expenses	$317.6M	$315.6M-0.9%	$318.5M-4.9%	$335.0M+2.6%	$326.5M+14.4%	$285.3M-14.2%	$332.6M-16.7%	$399.1M+17.2%	$340.4M+5.8%	$321.7M-7.1%	$346.2M-1.0%	$349.7M-17.6%	$424.5M+20.8%	$351.4M+2.4%	$343.0M
Operating Income	-$63.0M	-$61.6M+84.5%	-$396.2M-9533.3%	$4.2M-88.2%	$35.5M+191.0%	-$39.0M+19.6%	-$48.5M+12.9%	-$55.7M-11240.0%	$500K+101.2%	-$43.1M+59.8%	-$107.1M+21.1%	-$135.7M-243.9%	$94.3M-58.1%	$225.3M-1.2%	$228.0M
EBITDA	N/A	-$22.7M+93.5%	-$350.7M-797.2%	$50.3M-39.5%	$83.2M+11985.7%	-$700K+87.5%	-$5.6M+70.2%	-$18.8M-155.3%	$34.0M+107.3%	$16.4M+139.1%	-$41.9M+40.4%	-$70.3M-139.1%	$179.7M-39.0%	$294.5M+3.1%	$285.6M
Interest Expense	$7.2M	$7.8M-36.1%	$12.2M-18.7%	$15.0M+50.0%	$10.0M+203.0%	$3.3M-78.8%	$15.6M+4.0%	$15.0M-43.2%	$26.4M-16.5%	$31.6M-3.4%	$32.7M-1.2%	$33.1M+451.7%	$6.0M+5900.0%	$100K-87.5%	$800K
Income Tax	$6.1M	$6.7M+139.4%	-$17.0M-950.0%	$2.0M-61.5%	$5.2M+146.4%	-$11.2M+67.0%	-$33.9M-87.3%	-$18.1M-88.5%	-$9.6M+76.1%	-$40.1M+28.3%	-$55.9M+16.9%	-$67.3M-205.0%	$64.1M-12.4%	$73.2M-5.2%	$77.2M
Net Income	-$74.4M	-$72.9M+81.4%	-$392.1M-534.5%	-$61.8M-222.4%	$50.5M+701.6%	$6.3M+121.7%	-$29.0M+36.8%	-$45.9M-179.8%	$57.5M-27.5%	$79.3M+99.2%	$39.8M+109.3%	-$426.3M-1673.1%	$27.1M-82.5%	$154.6M+1.3%	$152.6M
EPS (Basic)	N/A	-$1.57+81.6%	-$8.53-546.2%	-$1.32-222.2%	$1.08+730.8%	$0.13+121.3%	-$0.61+36.5%	-$0.96-178.7%	$1.22-27.8%	$1.69+98.8%	$0.85+109.3%	-$9.15-1677.6%	$0.58-82.5%	$3.32+1.2%	$3.28
EPS (Diluted)	-$1.60	-$1.57+81.6%	-$8.53-546.2%	-$1.32-223.4%	$1.07+723.1%	$0.13+121.3%	-$0.61+36.5%	-$0.96-178.7%	$1.22-27.8%	$1.69+98.8%	$0.85+109.3%	-$9.15-1677.6%	$0.58-82.5%	$3.32+1.2%	$3.28
Diluted Shares (Avg)	N/A	46M+0.7%	46M-1.3%	47M-1.5%	47M-2.7%	49M+1.7%	48M+0.4%	48M+0.8%	47M+0.9%	47M+0.4%	47M0.0%	47M+0.2%	47M0.0%	47M	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$182.2M+8.8%	$180.9M+0.7%	$177.8M+4.3%	$175.0M+1.9%	$167.5M+0.8%	$179.6M+3.6%	$170.4M-0.5%	$171.7M+1.4%
Cost of Revenue	$88.0M+13.3%	$94.9M+16.3%	$91.8M+18.5%	$82.9M+8.9%	$77.7M+9.0%	$81.6M+4.2%	$77.5M+2.2%	$76.1M+6.3%
Gross Profit	$94.2M+4.9%	$86.0M-12.2%	$86.0M-7.4%	$92.1M-3.7%	$89.8M-5.3%	$98.0M+3.2%	$92.9M-2.7%	$95.6M-2.2%
R&D Expenses	$5.2M-3.7%	$6.1M+7.0%	$6.0M-16.7%	$5.8M-7.9%	$5.4M-22.9%	$5.7M-16.2%	$7.2M+18.0%	$6.3M-7.4%
SG&A Expenses	$77.7M+2.6%	$78.8M-1.1%	$77.6M+4.4%	$83.5M+3.2%	$75.7M-9.4%	$79.7M+7.0%	$74.3M-5.6%	$80.9M-13.0%
Operating Income	$8.9M-13.6%	$2.5M+100.6%	$100K-99.2%	-$74.5M-1282.5%	$10.3M+157.5%	-$418.5M-3836.6%	$12.0M+900.0%	$6.3M+400.0%
EBITDA	$19.1M-4.0%	$7.2M+101.8%	$21.7M-8.4%	-$71.5M-506.3%	$19.9M+29.2%	-$407.4M-1804.6%	$23.7M+94.3%	$17.6M+114.6%
Interest Expense	$1.5M-28.6%	$1.9M-32.1%	$1.8M-43.8%	$2.0M-35.5%	$2.1M-32.3%	$2.8M-15.2%	$3.2M-31.9%	$3.1M-11.4%
Income Tax	$2.5M-19.4%	$2.5M+110.6%	$200K-94.4%	$900K-52.6%	$3.1M+210.0%	-$23.5M-1019.0%	$3.6M-41.9%	$1.9M+337.5%
Net Income	$5.1M-22.7%	-$1.3M+99.7%	-$1.4M-132.6%	-$76.8M-4366.7%	$6.6M+833.3%	-$397.3M-3883.8%	$4.3M+216.2%	$1.8M+102.6%
EPS (Basic)	$0.11-21.4%	-$0.02+99.8%	-$0.03-133.3%	-$1.66-4250.0%	$0.14+800.0%	-$8.64-3856.5%	$0.09+212.5%	$0.04+102.7%
EPS (Diluted)	$0.11-21.4%	-$0.02+99.8%	-$0.03-133.3%	-$1.66-4250.0%	$0.14+800.0%	-$8.64-3856.5%	$0.09+212.5%	$0.04+102.7%
Diluted Shares (Avg)	48M+1.5%	N/A	46M-0.4%	46M0.0%	47M+0.2%	N/A	47M-0.4%	46M-1.1%

AVNS Balance Sheet

AVNS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.1B-7.0%	$1.2B-31.8%	$1.7B-5.3%	$1.8B+11.4%	$1.6B-4.1%	$1.7B-7.0%	$1.8B-1.8%	$1.8B-16.5%	$2.2B+6.0%	$2.1B+3.6%	$2.0B-20.6%	$2.5B+1.4%	$2.5B	N/A
Current Assets	$355.4M-9.7%	$393.4M-19.2%	$487.0M-22.0%	$624.1M+46.0%	$427.6M-8.5%	$467.2M-13.2%	$538.5M-24.5%	$713.6M-38.5%	$1.2B+95.6%	$593.5M-12.2%	$676.0M-1.1%	$683.6M+16.8%	$585.1M	N/A
Cash & Equivalents	$89.8M-16.6%	$107.7M+22.8%	$87.7M-31.3%	$127.7M+7.8%	$118.5M+6.3%	$111.5M-45.7%	$205.3M-46.6%	$384.5M+75.0%	$219.7M+93.2%	$113.7M-12.2%	$129.5M-13.1%	$149.0M+237.9%	$44.1M-7.9%	$47.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$148.0M+6.6%	$138.8M-15.0%	$163.2M+23.4%	$132.3M-16.9%	$159.3M-5.7%	$168.9M+15.8%	$145.9M+20.2%	$121.4M+33.3%	$91.1M+12.9%	$80.7M-73.4%	$303.2M+7.1%	$283.1M-0.9%	$285.6M	N/A
Accounts Receivable	$103.8M-21.8%	$132.8M-7.0%	$142.8M-14.9%	$167.9M+28.0%	$131.2M+20.8%	$108.6M-33.7%	$163.8M+8.8%	$150.5M-25.9%	$203.0M+7.7%	$188.5M-16.1%	$224.7M-3.9%	$233.9M+15.1%	$203.3M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$394.9M-13.3%	$455.6M-42.8%	$796.1M+4.7%	$760.3M+2.4%	$742.5M-7.5%	$802.5M+0.2%	$800.9M+2.2%	$783.6M+2.5%	$764.7M+0.3%	$762.3M+12.4%	$678.4M-52.4%	$1.4B-0.3%	$1.4B-0.3%	$1.4B
Total Liabilities	$295.5M-9.3%	$325.7M-28.6%	$456.1M-8.0%	$495.7M+48.9%	$333.0M-20.0%	$416.3M-22.1%	$534.4M-0.3%	$536.2M-45.3%	$980.5M+1.2%	$969.3M+2.6%	$944.9M-8.0%	$1.0B+153.6%	$404.9M	N/A
Current Liabilities	$165.2M-0.4%	$165.9M-29.3%	$234.6M+22.8%	$191.0M+37.2%	$139.2M-16.3%	$166.3M-21.7%	$212.5M-19.6%	$264.3M-32.2%	$389.8M+20.2%	$324.4M+2.9%	$315.2M-11.5%	$356.0M+14.7%	$310.4M	N/A
Non-Current Liabilities	$130.3M-18.5%	$159.8M-27.9%	$221.5M-27.3%	$304.7M+57.2%	$193.8M-22.5%	$250.0M-22.3%	$321.9M+18.4%	$271.9M-54.0%	$590.7M-8.4%	$644.9M+1149.8%	$51.6M+7.3%	$48.1M-49.1%	$94.5M	N/A
Long-Term Debt	$90.3M-27.9%	$125.3M-21.4%	$159.4M-29.6%	$226.3M+74.1%	$130.0M-27.8%	$180.0M-27.4%	$248.1M+0.2%	$247.7M-54.2%	$541.1M-6.5%	$579.0M+0.2%	$578.1M-7.1%	$622.6M	$0	N/A
Total Equity	$778.2M-6.1%	$828.5M-33.0%	$1.2B-4.3%	$1.3B+1.6%	$1.3B+0.7%	$1.3B-0.8%	$1.3B-1.9%	$1.3B+6.7%	$1.2B+10.2%	$1.1B+4.5%	$1.1B-29.2%	$1.5B-28.3%	$2.1B+1.1%	$2.1B
Retained Earnings	-$779.9M-10.3%	-$707.0M-124.5%	-$314.9M-24.4%	-$253.1M+16.6%	-$303.6M+3.8%	-$315.5M-9.4%	-$288.3M-18.9%	-$242.4M+19.2%	-$299.9M+20.9%	-$379.2M+9.5%	-$419.0M-5839.7%	$7.3M	$0	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$1.1B-5.2%	$1.1B-7.0%	$1.1B-35.5%	$1.0B-37.3%	$1.1B-33.3%	$1.2B-31.8%	$1.7B-4.0%	$1.7B-0.5%
Current Assets	$325.0M-7.8%	$355.4M-9.7%	$351.4M-25.6%	$356.0M-24.9%	$352.4M-24.7%	$393.4M-19.2%	$472.6M-9.9%	$474.1M-6.5%
Cash & Equivalents	$65.6M-32.4%	$89.8M-16.6%	$70.5M-20.8%	$90.3M-2.1%	$97.0M+28.0%	$107.7M+22.8%	$89.0M-16.9%	$92.2M+12.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$141.3M+2.3%	$148.0M+6.6%	$150.6M-7.0%	$142.7M-12.9%	$138.1M-16.6%	$138.8M-15.0%	$161.9M+3.4%	$163.9M+10.5%
Accounts Receivable	$103.0M-1.7%	$103.8M-21.8%	$111.5M-15.5%	$110.2M-10.4%	$104.8M-20.2%	$132.8M-7.0%	$131.9M-9.2%	$123.0M-19.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$394.0M-13.6%	$394.9M-13.3%	$394.4M-50.4%	$381.2M-52.0%	$455.9M-42.6%	$455.6M-42.8%	$795.1M+0.5%	$794.4M+4.2%
Total Liabilities	$268.0M-0.1%	$295.5M-9.3%	$289.7M-32.1%	$262.7M-39.7%	$268.4M-38.1%	$325.7M-28.6%	$426.5M-15.2%	$435.8M+0.9%
Current Liabilities	$131.2M-4.4%	$165.2M-0.4%	$147.9M-30.5%	$134.6M-35.4%	$137.2M-33.1%	$165.9M-29.3%	$212.9M+24.7%	$208.2M+29.7%
Non-Current Liabilities	$136.8M+4.3%	$130.3M-18.5%	$141.8M-33.6%	$128.1M-43.7%	$131.2M-42.5%	$159.8M-27.9%	$213.6M-35.7%	$227.6M-16.1%
Long-Term Debt	$87.3M-10.9%	$90.3M-27.9%	$93.4M-38.8%	$95.7M-42.0%	$98.0M-41.4%	$125.3M-21.4%	$152.6M-40.9%	$164.9M-18.9%
Total Equity	$782.1M-6.8%	$778.2M-6.1%	$778.0M-36.7%	$776.3M-36.5%	$839.4M-31.6%	$828.5M-33.0%	$1.2B+0.6%	$1.2B-1.0%
Retained Earnings	-$774.8M-10.6%	-$779.9M-10.3%	-$778.6M-151.4%	-$777.2M-147.5%	-$700.4M-121.8%	-$707.0M-124.5%	-$309.7M+4.8%	-$314.0M+2.4%

AVNS Cash Flow Statement

AVNS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$36.7M	$74.7M-25.8%	$100.7M+210.8%	$32.4M-64.4%	$90.9M+4.1%	$87.3M+3592.0%	-$2.5M+96.6%	-$74.5M+48.8%	-$145.6M-201.0%	$144.2M-23.6%	$188.8M+93.4%	$97.6M-34.0%	$147.9M-33.9%	$223.8M+10.5%	$202.6M
Depreciation & Amortization	N/A	$38.9M-14.5%	$45.5M-1.3%	$46.1M-3.4%	$47.7M+24.5%	$38.3M-10.7%	$42.9M+16.3%	$36.9M+10.1%	$33.5M-43.7%	$59.5M-8.7%	$65.2M-0.3%	$65.4M-23.4%	$85.4M+23.4%	$69.2M+20.1%	$57.6M
Stock-Based Compensation	N/A	$12.6M-8.7%	$13.8M-12.7%	$15.8M-0.6%	$15.9M+20.5%	$13.2M+9.1%	$12.1M+15.2%	$10.5M0.0%	$10.5M-16.7%	$12.6M-14.9%	$14.8M+5.0%	$14.1M+78.5%	$7.9M+31.7%	$6.0M+13.2%	$5.3M
Capital Expenditures	$29.2M	$31.6M+77.5%	$17.8M0.0%	$17.8M-7.8%	$19.3M-8.1%	$21.0M+4.0%	$20.2M-60.1%	$50.6M+3.1%	$49.1M+13.7%	$43.2M+48.5%	$29.1M-58.7%	$70.4M-10.3%	$78.5M+60.2%	$49.0M+20.1%	$40.8M
Free Cash Flow	$7.5M	$43.1M-48.0%	$82.9M+467.8%	$14.6M-79.6%	$71.6M+8.0%	$66.3M+392.1%	-$22.7M+81.9%	-$125.1M+35.7%	-$194.7M-292.8%	$101.0M-36.8%	$159.7M+487.1%	$27.2M-60.8%	$69.4M-60.3%	$174.8M+8.0%	$161.8M
Investing Cash Flow	-$59.2M	-$60.6M-120.4%	-$27.5M-227.3%	$21.6M+116.0%	-$135.4M-544.8%	-$21.0M+13.2%	-$24.2M+77.6%	-$108.1M-116.9%	$639.5M+1583.8%	-$43.1M+78.5%	-$200.9M-220.9%	-$62.6M+11.5%	-$70.7M-38.9%	-$50.9M-26.3%	-$40.3M
Financing Cash Flow	-$11.1M	-$37.0M+24.6%	-$49.1M+47.9%	-$94.2M-266.1%	$56.7M+202.5%	-$55.3M+21.0%	-$70.0M-4766.7%	$1.5M+100.5%	-$324.4M-14845.5%	$2.2M+257.1%	-$1.4M+97.2%	-$50.6M-273.3%	$29.2M+116.2%	-$180.0M-34.4%	-$133.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$2.4M	$3.3M-74.2%	$12.8M-33.0%	$19.1M-58.0%	$45.5M+295.7%	$11.5M+1177.8%	$900K-75.0%	$3.6M+300.0%	$900K-64.0%	$2.5M+177.8%	$900K-10.0%	$1.0M	$0	$0	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$12.3M-147.9%	$28.2M-51.3%	$14.0M-39.1%	$6.8M-75.5%	$25.7M+421.3%	$57.9M+355.9%	$23.0M-21.0%	$27.8M+1169.2%
Depreciation & Amortization	$10.2M+6.3%	$9.9M-10.8%	$21.6M+84.6%	$3.0M-73.5%	$9.6M-15.8%	$11.1M-3.5%	$11.7M+6.4%	$11.3M+9.7%
Stock-Based Compensation	$3.7M-2.6%	N/A	$3.5M+34.6%	$4.1M+7.9%	$3.8M+5.6%	N/A	$2.6M-33.3%	$3.8M-2.6%
Capital Expenditures	$4.3M-35.8%	$6.9M+43.8%	$7.0M+133.3%	$11.0M+86.4%	$6.7M+63.4%	$4.8M-18.6%	$3.0M-23.1%	$5.9M+47.5%
Free Cash Flow	-$16.6M-187.4%	$21.3M-59.9%	$7.0M-65.0%	-$4.2M-119.2%	$19.0M+257.0%	$53.1M+680.9%	$20.0M-20.6%	$21.9M+431.8%
Investing Cash Flow	-$7.7M+15.4%	-$6.8M+10.5%	-$31.5M-162.5%	-$13.2M-123.7%	-$9.1M-355.0%	-$7.6M-109.4%	-$12.0M+75.5%	-$5.9M+9.2%
Financing Cash Flow	-$3.2M+89.0%	-$2.7M+90.1%	-$2.0M+87.5%	-$3.2M+36.0%	-$29.1M-4057.1%	-$27.4M+76.1%	-$16.0M-134.3%	-$5.0M-22.0%
Share Buybacks	$1.3M-40.9%	$300K+200.0%	$0-100.0%	$800K-77.1%	$2.2M-75.8%	$100K-98.4%	$100K-98.9%	$3.5M+34.6%

Not reported in any period shown, so not listed: Dividends Paid.

AVNS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVNS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	50.5%-5.0pp	55.4%-0.9pp	56.4%-1.2pp	57.6%+6.7pp	51.0%-0.9pp	51.9%-5.8pp	57.6%-2.3pp	59.9%+4.8pp	55.1%+2.6pp	52.5%+1.8pp	50.6%+17.8pp	32.8%-3.7pp	36.5%+0.7pp	35.8%
Operating Margin	-8.8%+48.8pp	-57.6%-58.2pp	0.6%-4.6pp	5.2%+11.8pp	-6.6%+0.2pp	-6.8%+1.2pp	-8.0%-8.1pp	0.1%+7.1pp	-7.0%+11.9pp	-18.9%+7.7pp	-26.7%-32.3pp	5.6%-7.8pp	13.4%-0.1pp	13.5%
Net Margin	-10.4%+46.6pp	-57.0%-47.8pp	-9.2%-16.6pp	7.4%+6.3pp	1.1%+5.1pp	-4.1%+2.5pp	-6.6%-15.4pp	8.8%-4.2pp	13.0%+5.9pp	7.0%+90.8pp	-83.8%-85.4pp	1.6%-7.6pp	9.2%+0.2pp	9.1%
Return on Equity	-9.4%+38.0pp	-47.3%-42.3pp	-5.0%-8.9pp	3.9%+3.4pp	0.5%+2.8pp	-2.3%+1.3pp	-3.6%-8.0pp	4.4%-2.1pp	6.5%+2.9pp	3.6%+44.0pp	-40.4%-42.2pp	1.8%-5.6pp	7.4%0.0pp	7.4%
Return on Assets	-6.8%+27.2pp	-34.0%-30.3pp	-3.6%-6.5pp	2.8%+2.4pp	0.4%+2.1pp	-1.7%+0.8pp	-2.5%-5.7pp	3.1%-0.5pp	3.6%+1.7pp	1.9%+23.2pp	-21.3%-22.4pp	1.1%-5.1pp	6.2%	N/A
Current Ratio	2.15-0.2x	2.37+0.3x	2.08-1.2x	3.27+0.2x	3.07+0.3x	2.81+0.3x	2.53-0.2x	2.70-0.3x	2.98+1.1x	1.83-0.3x	2.14+0.2x	1.920.0x	1.89	N/A
Debt-to-Equity	0.120.0x	0.150.0x	0.130.0x	0.18+0.1x	0.100.0x	0.14-0.1x	0.200.0x	0.19-0.3x	0.45-0.1x	0.530.0x	0.55+0.1x	0.42+0.4x	0.00	N/A
Asset Turnover	0.65+0.1x	0.60+0.2x	0.400.0x	0.380.0x	0.37-0.1x	0.430.0x	0.390.0x	0.36+0.1x	0.280.0x	0.270.0x	0.25-0.4x	0.660.0x	0.68	N/A
FCF Margin	6.2%-5.9pp	12.0%+9.9pp	2.2%-8.3pp	10.5%-0.8pp	11.3%+14.5pp	-3.2%+14.8pp	-17.9%+11.9pp	-29.8%-46.4pp	16.5%-11.7pp	28.2%+22.9pp	5.3%+1.2pp	4.2%-6.3pp	10.4%+0.8pp	9.6%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	51.7%-1.9pp	47.5%-7.0pp	48.4%-6.2pp	52.6%-3.0pp	53.6%-3.5pp	54.6%-0.3pp	54.5%-1.2pp	55.7%-2.1pp
Operating Margin	4.9%-1.3pp	1.4%	0.1%-7.0pp	-42.6%-46.2pp	6.2%+3.7pp	-233.0%	7.0%+6.3pp	3.7%+4.9pp
Net Margin	2.8%-1.1pp	-0.7%	-0.8%-3.3pp	-43.9%-44.9pp	3.9%+4.5pp	-221.2%	2.5%+4.7pp	1.1%+41.3pp
Return on Equity	0.7%-0.1pp	-0.2%+47.8pp	-0.2%-0.5pp	-9.9%-10.0pp	0.8%+0.9pp	-48.0%-48.8pp	0.4%+0.7pp	0.1%+5.7pp
Return on Assets	0.5%-0.1pp	-0.1%+34.3pp	-0.1%-0.4pp	-7.4%-7.5pp	0.6%+0.7pp	-34.4%-35.0pp	0.3%+0.5pp	0.1%+4.2pp
Current Ratio	2.48-0.1x	2.15-0.2x	2.38+0.2x	2.64+0.4x	2.57+0.3x	2.37+0.3x	2.22-0.9x	2.28-0.9x
Debt-to-Equity	0.110.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.150.0x	0.12-0.1x	0.130.0x
Asset Turnover	0.170.0x	0.170.0x	0.17+0.1x	0.17+0.1x	0.15+0.1x	0.16+0.1x	0.100.0x	0.100.0x
FCF Margin	-9.1%-20.5pp	11.8%-17.8pp	3.9%-7.8pp	-2.4%-15.2pp	11.3%+18.6pp	29.6%+25.7pp	11.7%-3.0pp	12.8%+16.7pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Avanos Medical, Inc. AVNS	FY2025	$701.2M	-$72.9M	-10.4%	$1.2B	44/100
Orthofix Medical Inc. OFIX	FY2025	$822.3M	-$92.2M	-11.2%	$363.7M	43/100
ZimVie Inc. ZIMV	FY2024	$449.7M	-$25.8M	-5.7%	$535.7M	23/100
Bioventus Inc. BVS	FY2025	$568.1M	$22.7M	4.0%	$886.6M	42/100
SI-BONE, Inc. SIBN	FY2025	$200.9M	-$18.9M	-9.4%	$823.8M	53/100
Cytek Biosciences, Inc. CTKB	FY2025	$201.5M	-$66.5M	-33.0%	$599.2M	45/100

Where Avanos Medical, Inc. Ranks

Frequently Asked Questions

What is Avanos Medical, Inc.'s annual revenue?

Avanos Medical, Inc. (AVNS) reported $701.2M in total revenue for fiscal year 2025. This represents a 1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Avanos Medical, Inc.'s revenue growing?

Avanos Medical, Inc. (AVNS) revenue grew by 1.9% year-over-year, from $687.8M to $701.2M in fiscal year 2025.

Is Avanos Medical, Inc. profitable?

No, Avanos Medical, Inc. (AVNS) reported a net income of -$72.9M in fiscal year 2025, with a net profit margin of -10.4%.

What is Avanos Medical, Inc.'s EBITDA?

Avanos Medical, Inc. (AVNS) had EBITDA of -$22.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Avanos Medical, Inc. have?

As of fiscal year 2025, Avanos Medical, Inc. (AVNS) had $89.8M in cash and equivalents against $90.3M in long-term debt.

What is Avanos Medical, Inc.'s gross margin?

Avanos Medical, Inc. (AVNS) had a gross margin of 50.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Avanos Medical, Inc.'s operating margin?

Avanos Medical, Inc. (AVNS) had an operating margin of -8.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Avanos Medical, Inc.'s net profit margin?

Avanos Medical, Inc. (AVNS) had a net profit margin of -10.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Avanos Medical, Inc.'s return on equity (ROE)?

Avanos Medical, Inc. (AVNS) has a return on equity of -9.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Avanos Medical, Inc.'s free cash flow?

Avanos Medical, Inc. (AVNS) generated $43.1M in free cash flow during fiscal year 2025. This represents a -48.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Avanos Medical, Inc.'s operating cash flow?

Avanos Medical, Inc. (AVNS) generated $74.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Avanos Medical, Inc.'s total assets?

Avanos Medical, Inc. (AVNS) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Avanos Medical, Inc.'s capital expenditures?

Avanos Medical, Inc. (AVNS) invested $31.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Avanos Medical, Inc. spend on research and development?

Avanos Medical, Inc. (AVNS) invested $23.3M in research and development during fiscal year 2025.

Does Avanos Medical, Inc. buy back shares?

Yes, Avanos Medical, Inc. (AVNS) spent $3.3M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Avanos Medical, Inc. have outstanding?

Avanos Medical, Inc. (AVNS) had 47M shares outstanding as of fiscal year 2025.

What is Avanos Medical, Inc.'s current ratio?

Avanos Medical, Inc. (AVNS) had a current ratio of 2.15 as of fiscal year 2025, which is generally considered healthy.

What is Avanos Medical, Inc.'s debt-to-equity ratio?

Avanos Medical, Inc. (AVNS) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avanos Medical, Inc.'s return on assets (ROA)?

Avanos Medical, Inc. (AVNS) had a return on assets of -6.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avanos Medical, Inc.'s Altman Z-Score?

Avanos Medical, Inc. (AVNS) has an Altman Z-Score of 2.04, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Avanos Medical, Inc.'s Piotroski F-Score?

Avanos Medical, Inc. (AVNS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avanos Medical, Inc.'s earnings high quality?

Avanos Medical, Inc. (AVNS) reported a net loss of $72.9M while generating $74.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Avanos Medical, Inc. cover its interest payments?

Avanos Medical, Inc. (AVNS) reported an operating loss of $61.6M against $7.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Avanos Medical, Inc.?

Avanos Medical, Inc. (AVNS) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.